ORCiD numbers: 0000-0002-5531-4416 (M. Morkos); 0000-0002-7812-6370 (A. Bindal).
Participant:
A 29-year-old Hispanic woman with known history of long-standing, uncontrolled T1DM presented for evaluation of worsening dysphagia and dyspnea. She was found to have cervical necrotizing fasciitis extending into the mediastinum and required several debridement surgeries along with broad-spectrum antibiotics and antifungal therapy. She had uncontrolled diabetes with a glycosylated hemoglobin of 13.4% (18.8 mM) on admission. Her insulin requirements progressively increased as a result of worsening infection, continuous tube feeds, and multiple debridement surgeries. She was started on micafungin, a potent 1,3-b-D glucan synthase inhibitor, to broaden antimicrobial coverage when her insulin requirement decreased to zero for .48 hours. Right after discontinuation of micafungin and her switch to a different antifungal, insulin requirements increased back to her baseline needs.
Results: This is a report of decreased insulin requirements in a patient with T1DM correlating with micafungin administration. The mechanism of micafungin-induced hypoglycemia is not yet established. Oral administration of linear 1,3-b-D glucan has been documented to decrease blood glucose levels significantly by inhibition of expression of sodium-glucose transporter 1 (SGLT1) in intestinal mucosa. She was recently admitted to an outside facility for epiglottitis and diagnosed with her first episode of diabetic ketoacidosis (DKA), after which she was discharged on oral clindamycin. As her condition worsened, she presented to our facility with another episode of DKA. A CT scan revealed soft-tissue infection of the neck and chest wall extending into the mediastinum, concerning for necrotizing fasciitis with mediastinal abscess. Aggressive fluid resuscitation and broad-spectrum antimicrobials were started including vancomycin, levofloxacin, cefepime, clindamycin, and fluconazole. She also necessitated multiple operative procedures for the persistent abscess. Her course was complicated by respiratory failure requiring intubation, as well as cardiac arrest, intraoperatively during one of the surgical drainages.
Conclusion
On the 25th day of her hospitalization, she became febrile and developed progressive leukocytosis. Subsequently, fluconazole was switched to micafungin 100 mg IV daily (administered in normal saline) for broader antifungal coverage. Before starting micafungin therapy, her total daily insulin dose was .120 units, as shown in Fig. 1 . At that time, she was receiving continuous tube feeds at the goal rate, and her estimated glomerular filtration rate (GFR) was .60 mL/min/ 1.73 m 2 . She did experience acute kidney injury right before micafungin was initiated, and this progressed until her 33rd day of hospitalization (day 8 after micafungin was initiated), as shown in Fig. 1 . Her worst GFR was 25 mL/min/1.73 m 2 , after which her kidney dysfunction steadily resolved, and her kidney function went back to normal with GFR . 60 mL/min/1.73 m 2 by hospital day 38. After initiation of micafungin therapy, her insulin requirements and blood glucose (BG) levels drastically decreased. She experienced her first episode of severe hypoglycemia (point of care BG: 31 mg/dL) despite remaining on the same tube feeds and subsequently did not require insulin for .48 hours with an average BG ,120 mg/dL. Of note, her point of care glucose correlated with her glucose on venous blood test results, and she did not experience gastrointestinal side effects. We recommended starting dextrose infusion at that time, along with insulin administration (10 units), to avoid DKA. Upon micafungin therapy discontinuation, insulin requirements progressively increased, and by postmicafungin day 5, 70 units of insulin was required per day. Although she had acute kidney injury, her insulin requirements went back up before her kidney dysfunction resolved, and in fact, her kidney function continued to deteriorate during the time her insulin requirements were back up to 70 units of insulin per day.
Discussion
T1DM is a condition of insulin deficiency, and therapy with insulin is the mainstay of treatment (1). Although it is common knowledge that insulin can cause hypoglycemia, other medication-induced hypoglycemia is also a well-described phenomenon. Mechanisms include stimulation of intrinsic insulin release, decreased insulin clearance, inhibition of gluconeogenesis, and increased insulin sensitivity (2) . The former two mechanisms depend on the intrinsic activity of insulin, whereas the latter two are based on improvement of insulin resistance. Although these mechanisms may explain hypoglycemia in many patients, they would not explain why a patient with T1DM needs no insulin for .48 hours, as in our patient. We are reporting a case of micafungin-induced hypoglycemia in a patient with T1DM.
Micafungin, an echinocandin antifungal, is a noncompetitive inhibitor of 1,3-b-D glucan formation, a Figure 1 . Trend of average daily blood glucose (BG) measurements, total daily carbohydrate intake (including tube feeds), total daily insulin, glomerular filtration rate (GFR), and micafungin administration. Average daily BG measurements are represented as a blue line; total daily carbohydrate intake is represented as a gray line; total daily insulin is represented as an orange line; and GFR is represented as a yellow line. Each day contains one data point for each of these variables. Duration of micafungin administration is represented as a light blue. (4) . Caspofungin, an older member in the echinocandin family, was shown to unmask b-glucan, resulting in increased activity and interaction with immune cells (5) . It has been shown that oral 1, 3-b-D glucan administration in obese mice with type 2 diabetes mellitus leads to lower BG and weight loss by suppressing the expression of the sodium-glucose transporter 1 (SGLT-1) in the intestinal mucosa (6) . Furthermore, oat b-glucan was shown to downregulate SGLT-1 and glucose transporter 2 (GLUT2) in the intestine (7). We hypothesize that micafungin, like caspofungin, may unmask the intestinal b-glucans and subsequently increase the activity of their receptors (5) . Of note, b-glucan receptors are widely expressed in humans, including monocytes, macrophages, neutrophils, eosinophils, B cells, and a subpopulation of T cells (8) .
SGLT-1 is present in the intestinal luminal brush border and to a lesser extent in the renal tubules. SGLT-1 was identified in cells secreting glucose-dependent insulinotropic peptide and glucagon-like peptide 1 (9) . Its presence is important for D-glucose and galactose absorption, upregulation of GLUT2, release of glucosedependent insulinotropic peptide and glucagon-like peptide 1, and glucose reabsorption from the kidney (;3% of the filtered load) (9) . Sodium-GLUT2 (SGLT-2) is another member in the same family that is predominantly expressed in the kidney and promotes ;90% of glucose reabsorption from the filtered load. SGLT-2 inhibitors have been shown to cause a substantial decrease in BG in patients with type 2 diabetes mellitus, and there are now several approved medications on the market for this purpose (10) . SGLT-1 was extensively studied in the past, and several inhibitors are under investigation for clinical use in patients with diabetes. These SGLT-1 inhibitors would reduce glucose absorption in the intestines and also have a mild glucosuric effect (11) . Sotagliflozin, a nonselective inhibitor of SGLT-1 and SGLT-2, was recently shown to achieve positive outcomes in patients with T1DM and is currently under US Food and Drug Administration review (12) .
Our patient with T1DM was receiving continuous tube feeds with a high carbohydrate load (shown in Fig. 1 ) and was significantly insulin resistant as a result of her severe underlying necrotizing fasciitis and soft-tissue abscesses. Renal wasting of glucose was ruled out by lack of glucosuria. Therefore, lack of insulin production with intact renal retention of glucose suggests that poor gastrointestinal absorption, as well decreased SGLT-1-mediated glucose-dependent hormone release and GLUT2 upregulation could be contributing to her decreased insulin needs. There was a clear temporal relationship between when her insulin needs drastically reduced and micafungin was started (13) . Subsequently, there was also a clear temporal relationship between micafungin therapy discontinuation and a progressive increase in insulin requirements as micafungin was cleared from the body. This temporal relationship is further supported by micafungin pharmacokinetics. Half-life of micafungin is 14 6 1 hour; therefore, it would take ;3 to 4 days (or 5 to 6 half-lives) for 98% elimination of micafungin, which is consistent with our patient's BG increasing on day 5 of micafungin being stopped. Although she did experience acute kidney injury, her insulin needs increased again after discontinuation of micafungin despite her renal function worsening for several more days. The underlying process of how micafungin contributed to this patient's reduced insulin needs may represent an approach for diabetes management in patients with T1DM. Further studies are needed to assess the efficacy of SGLT-1 inhibition in patients with T1DM. Furthermore, some patients may need adjustment of their insulin dose while on micafungin therapy.
Conclusion
Micafungin may contribute to hypoglycemia in patients with T1DM through inhibition of SGLT-1.
